Relafen 750, pharmacologically known as naproxen, represents a noteworthy case study from a biochemical pharmacy standpoint. The drug exhibits its therapeutic effect primarily by inhibiting the activity of more info cyclooxygenase (COX) enzymes, specifically COX-2, thereby decreasing prostaglandin synthesis . The targeted inhibition of COX-2, compa